Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zynex ( (ZYXI) ) has provided an update.
On October 1, 2025, Zynex, Inc. announced a strategic shift to seek a commercialization partner for its NiCO™ CO-Oximeter instead of pursuing independent commercialization. This decision led to the termination of most employees at Zynex Monitoring Solutions, Inc., resulting in expected cost savings and pre-tax charges, including $0.1 million for severance and up to $31.0 million for asset impairment. The company aims to continue seeking third-party commercialization opportunities, though success is not guaranteed.
The most recent analyst rating on (ZYXI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
Spark’s Take on ZYXI Stock
According to Spark, TipRanks’ AI Analyst, ZYXI is a Neutral.
Zynex’s overall stock score is primarily impacted by its financial struggles, including declining revenues and profitability, and increased leverage. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. While the earnings call provides some hope with cost reduction and strategic refocus, these efforts are overshadowed by the current challenges.
To see Spark’s full report on ZYXI stock, click here.
More about Zynex
Zynex, Inc. operates in the medical technology industry, focusing on developing and providing medical devices. Its subsidiary, Zynex Monitoring Solutions, Inc., developed the NiCO™ CO-Oximeter, a multi-parameter pulse oximeter.
Average Trading Volume: 239,675
Technical Sentiment Signal: Sell
Current Market Cap: $44.54M
For detailed information about ZYXI stock, go to TipRanks’ Stock Analysis page.